Please assess the completion status of the following clinical trial:

Trial Title: 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 1-year history of migraine with or without aura consistent with a diagnosis.~* Age of the participant at the time of migraine onset \<50 years.~Exclusion Criteria:~* Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine.~* Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy.~* History of an inadequate response to \>4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine.~* Participants with clinically significant hematologic, endocrine, cardiovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching atogepant tablets orally once daily for 12 weeks.
- Atogepant 10 mg (Type: EXPERIMENTAL): Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
- Atogepant 30 mg (Type: EXPERIMENTAL): Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
- Atogepant 60 mg (Type: EXPERIMENTAL): Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).